Komen Scholar Spotlight
Dawn L. Hershman, M.D., M.S., is Professor of Medicine and Epidemiology and Director of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center. Dr. Hershman’s expertise includes breast cancer treatment, prevention, survivorship, late-effects of cancer therapy, health outcomes and health disparities research. A clinician-scientist, Dr. Hershman’s research interests focus on understanding ways to improve breast cancer outcomes by identifying factors that are associated with suboptimal breast cancer therapy and conducting clinical trials aiming at predicting which patients may be more susceptible to experience either treatment or financial toxicities related to their breast cancer care. Dr. Hershman investigates over-use of procedures and drugs with uncertain benefit to the patient. Her Komen Scholar grant focuses on better understanding the impact of comorbidity, such as diabetes and hypertension, on complications and outcomes of cancer therapy, on breast cancer outcomes (toxicity, survival and healthcare utilization) and how clinical trials can be generalized to avoid an underestimation of the true efficacy and toxicity in the general population.